BLA 761195 · Argenx Bv
Vyvgart
Efgartigimod Alfa · Injection · Neonatal Fc Receptor Blocker
NovelOrphanCDER novel approval, Dec 17, 2021: To treat generalized myasthenia gravis
Last checked: Nov 20, 2026Latest source record: May 8, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2021
Dec 17, 2021
Approved uses
4
Original approval plus efficacy supplements
Registered trials
35
9 Phase 3, 9 recruiting
FAERS reports
3,968
3,661 serious, 379 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect May 13, 2026.
VYVGART is indicated for the treatment of adult patients with generalized myasthenia gravis (gMG). VYVGART is a neonatal Fc receptor blocker indicated for the treatment of adult patients with generalized myasthenia gravis (gMG). ( 1 )
Mechanism: Efgartigimod alfa-fcab is a human IgG1 antibody fragment that binds to the neonatal Fc receptor (FcRn), resulting in the reduction of circulating IgG.
Therapeutic areas: Neurology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 8, 2026 Supplement 16 · Efficacy · priority review OrphanLetterLabel
- Oct 17, 2025 Supplement 12 · Efficacy OrphanLabelLetter
- Aug 8, 2024 Supplement 4 · Efficacy OrphanLetterLabel
- Dec 17, 2021 Original approval · Type 1 - New Molecular Entity NovelOrphanLabelLetterReview
1 products under this application
- VYVGART · EFGARTIGIMOD ALFA 400MG · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Efgartigimod Alfa" as an intervention, any sponsor and status, largest first.
argenxargenx (ARGX)
NCT04280718 · 229 participants · Start Sep 18, 2020 · Primary completion Apr 30, 2027
Drug: Efgartigimod PH20 SC · For: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Sites: Birmingham, Alabama; Phoenix, Arizona; Scottsdale, Arizona · 147 sites in all
- A Study to Learn About How Well the Medicine Efgartigimod Works to Treat Autoimmune Encephalitis In Children 12 Years or Older and AdultsPivotal-lookingNot yet recruiting
argenxargenx (ARGX)
NCT07583641 · 170 participants (planned) · Start Apr 1, 2027 · Primary completion Jul 2030
Drug: Efgartigimod PH20 (ARGX-113) SC · For: Autoimmune Encephalitis (AE)
Sites: Tucson, Arizona; Sherman, Texas
- An Efficacy and Safety Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle WeaknessPivotal-lookingCompleted
argenxargenx (ARGX)
NCT03669588 · 167 participants · Start Aug 22, 2018 · Primary completion Apr 6, 2020
Drug: ARGX-113; Placebo · For: Generalized Myasthenia Gravis
Sites: Phoenix, Arizona; Carlsbad, California; Los Angeles, California · 66 sites in all
- A Safety and Tolerability Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness.Pivotal-lookingCompleted
argenxargenx (ARGX)
NCT03770403 · 151 participants · Start Mar 1, 2019 · Primary completion Jun 23, 2022
Drug: ARGX-113 · For: Generalized Myasthenia Gravis
Sites: Carlsbad, California; Los Angeles, California; Orange, California · 52 sites in all
- A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP).Pivotal-lookingCompleted
argenxargenx (ARGX)
NCT04188379 · 131 participants · Start Dec 16, 2019 · Primary completion Feb 3, 2022
Drug: efgartigimod · For: Primary Immune Thrombocytopenia
Sites: Tucson, Arizona; Washington D.C., District of Columbia; Jacksonville, Florida · 121 sites in all
- Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia GravisPivotal-lookingRecruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT07217587 · 115 participants (planned) · Start Jan 5, 2026 · Primary completion Sep 28, 2027
Drug: Nipocalimab; Efgartigimod · For: Myasthenia Gravis
Sites: Fullerton, California; Pomona, California; Colorado Springs, Colorado · 31 sites in all
- Efficacy and Safety of Efgartigimod in the Treatment of Guillain-Barré Syndrome(GREAT)Pivotal-lookingNot yet recruiting
Beijing Tiantan HospitalAcademic, hospital or other
NCT07806916 · 110 participants (planned) · Start Sep 2026 · Primary completion Jun 2027
Drug: Intravenous immunoglobulin (IVIG); Efgartigimod Alfa-Fcab · For: Guillain-Barré Syndrome
- A Long-term Study to Assess the Safety and Efficacy of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP).Pivotal-lookingCompleted
argenxargenx (ARGX)
NCT04225156 · 101 participants · Start Jun 2, 2020 · Primary completion Mar 11, 2026
Drug: efgartigimod · For: Primary Immune Thrombocytopenia
Sites: Washington D.C., District of Columbia; Ocala, Florida; Iowa City, Iowa · 87 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- myasthenia gravis785
- myasthenia gravis crisis455
- fatigue404
- dyspnoea301
- asthenia263
- fall224
- drug ineffective216
- urinary tract infection214
- muscular weakness199
- headache192
- death191
- dysphagia179
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2020 | 5 |
| 2021 | 3 |
| 2022 | 349 |
| 2023 | 1,194 |
| 2024 | 1,669 |
| 2025 | 451 |
| 2026 | 297 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Vyvgart (Efgartigimod Alfa-Fcab)
2024 spending
$241M
Beneficiaries
947
4,872 claims
Per beneficiary
$254,275
$307.61 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $75,471,019 |
| 2023 | $200,002,141 |
| 2024 | $240,798,682 |
Part B: Vyvgart (Efgartigimod Alfa-Fcab) · HCPCS J9332
2024 spending
$417M
Beneficiaries
1,803
23,690 claims
Per beneficiary
$231,053
2024 ASP limit $32.21 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $84,680,124 |
| 2023 | $297,337,988 |
| 2024 | $416,589,121 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial.
Allen JA, Lin J, Basta I, et al. · Lancet Neurol 2024 · Randomized Controlled Trial, Multicenter Study
- Comparative efficacy, safety, and functional recovery of neonatal fc receptor inhibitors and conventional immunotherapies for chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review and network meta-analysis.
Jiang Q, Gu Z · Front Immunol 2026 · Network Meta-Analysis, Systematic Review
- Efgartigimod Alfa in Generalised Myasthenia Gravis: A Profile of Its Use.
Heo YA · CNS Drugs 2023 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Post Hoc, Sex-Specific Subgroup Analysis of Efgartigimod in Patients With Generalized Myasthenia Gravis From the ADAPT Trial: A Sex and Gender Equity in Research (SAGER) Guidelines Approach.
Hoffmann S, Zhao S, Callewaert F, et al. · Muscle Nerve 2026 · Randomized Controlled Trial, Clinical Trial, Phase III
- A case of IgG4-related spinal pachymeningitis with a large spinal cord cavity: case report and updated systematic review.
Zhu J, Yu Y, Sun P, et al. · Neurol Sci 2025 · Case Reports, Systematic Review
Sponsor: argenx
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.